TWI542877B - Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein - Google Patents

Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein Download PDF

Info

Publication number
TWI542877B
TWI542877B TW101128365A TW101128365A TWI542877B TW I542877 B TWI542877 B TW I542877B TW 101128365 A TW101128365 A TW 101128365A TW 101128365 A TW101128365 A TW 101128365A TW I542877 B TWI542877 B TW I542877B
Authority
TW
Taiwan
Prior art keywords
amount
sugar chain
alzheimer
disease
protein
Prior art date
Application number
TW101128365A
Other languages
English (en)
Chinese (zh)
Other versions
TW201314207A (zh
Inventor
Katsuya Urakami
Miyako Kimura
Original Assignee
Nat Univ Corp Tottori Univ
Hyper Brain Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tottori Univ, Hyper Brain Co Ltd filed Critical Nat Univ Corp Tottori Univ
Publication of TW201314207A publication Critical patent/TW201314207A/zh
Application granted granted Critical
Publication of TWI542877B publication Critical patent/TWI542877B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW101128365A 2011-08-09 2012-08-07 Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein TWI542877B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011173946 2011-08-09

Publications (2)

Publication Number Publication Date
TW201314207A TW201314207A (zh) 2013-04-01
TWI542877B true TWI542877B (zh) 2016-07-21

Family

ID=47668469

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101128365A TWI542877B (zh) 2011-08-09 2012-08-07 Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein

Country Status (3)

Country Link
JP (1) JP5892169B2 (fr)
TW (1) TWI542877B (fr)
WO (1) WO2013021962A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045065A1 (fr) * 2019-09-02 2021-03-11 富士レビオ株式会社 Méthode de mesure d'une substance de liaison à la lectine, kit de mesure d'une substance de liaison à la lectine et support de capture à utiliser dans cette dernière
JPWO2021045061A1 (fr) * 2019-09-02 2021-03-11
CN113311056B (zh) * 2021-05-10 2022-06-21 中国医学科学院北京协和医院 用于遗传性血管水肿的标志物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207469B2 (ja) * 2006-09-06 2013-06-12 国立大学法人鳥取大学 アルツハイマーの診断キット、診断マーカー及び病態指標の検出方法

Also Published As

Publication number Publication date
JPWO2013021962A1 (ja) 2015-03-05
WO2013021962A1 (fr) 2013-02-14
JP5892169B2 (ja) 2016-03-23
TW201314207A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
JP5207469B2 (ja) アルツハイマーの診断キット、診断マーカー及び病態指標の検出方法
US20220146535A1 (en) Compounds and methods targeting human tau
KR101531949B1 (ko) 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
US20050124016A1 (en) Antibodies specific for toxic amyloid beta protein oligomers
JP7457337B2 (ja) アルツハイマー病バイオマーカー
US8609346B2 (en) Method for diagnosing alzheimer's disease using serum glycoprotein as biomarker
EP3457133A1 (fr) Marquer diagnostique de la démence et procédé d'identification de la survenance de la démence à l'aide dudit marqueur
US20090104629A1 (en) Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening
TWI542877B (zh) Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein
US9835621B2 (en) Process for detection of alzheimer's disease from a serum sample
EP3361257B1 (fr) Procédé et kit de diagnostic de la maladie d'alzheimer à l'aide de la protéine g72 et de l'arnm slc7a11 en tant que biomarqueurs
EP2646462B1 (fr) Méthodes et compositions de contrôle de l'activité phagocytaire
WO2020255938A1 (fr) Marqueur de diagnostic pour trouble cognitif léger
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
US20220308073A1 (en) Biomarker for alzheimer's disease
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
JP2014122788A (ja) アルカデインペプチド切断物による認知症又はアルツハイマー病の診断方法又は予後予測方法
Dayarathna et al. Nanoscale flow cytometry‐based quantification of blood‐based extracellular vesicle biomarkers distinguishes MCI and Alzheimer's disease
JP2017106884A (ja) 甲状腺刺激ホルモンレセプター抗体アイソタイプ測定を用いたバセドウ病の病態診断キット及びバセドウ病の病態の診断方法
EP2924437B1 (fr) Méthode de détection de maladie neurologique accompagnée d'une inflammation et/ou d'une démyélinisation
JPWO2012032766A1 (ja) 血中可溶型ｇｐｖｉを用いたアルツハイマー病の診断方法
WO2007042897A1 (fr) Procede de diagnostic differentiel et de surveillance de la demence de type alzheimer
JP2005145837A (ja) アルツハイマー病の診断方法